Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
HS-10509 in healthy adults and schizophrenia patients
NCT06301074Phase 1Not yet recruiting
- Sponsor
- Hansoh Pharmaceutical Group
- Start
- Mar 2024
- Primary completion
- May 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of HS-10509 in schizophrenia (4 arms), sponsored by Hansoh Pharmaceutical Group. Primary endpoints: Incidence and severity of adverse events at Day 42, Changes from baseline in lab tests at Day 35 and 7 more. Planned start Mar 2024; status: not yet recruiting.
02
Drugs
HS-10509
03
Conditions
schizophrenia
Beyond the preview
Go deeper on NCT06301074.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06301074.